Ibuprofen-Paracetamol Combination-Where Does it Stand in 2025?

The ibuprofen-paracetamol combination remains a cornerstone in pain management in 2025, offering synergistic efficacy and acceptable safety profiles. The ibuprofen-paracetamol consist of the analgesic and antipyretic strengths of paracetamol with the anti-inflammatory benefits of ibuprofen. It has been extensively studied for its efficacy and safety in managing acute and chronic conditions, including post-surgical pain and musculoskeletal disorders. With growing concerns about opioid use and advancements in combination formulations, a fixed-dose combination of ibuprofen and acetaminophen has remained a promising consideration as an alternative to opioids and other NSAIDs in a range of pain and fever management scenarios. This article reviews the current status, clinical applications, safety, and efficacy.

Ibuprofen Paracetamol Combination – Wide Range of Approved Indications with Robust Evidence

The ibuprofen-paracetamol combination is approved for various indications, including:

• Acute Pain: Low back pain (1), earache, headache, and musculoskeletal injuries. (2)
• Postoperative Pain: Dental surgeries (e.g., third molar extractions) and orthopedic procedures. (3)
• Dysmenorrhea: Primary menstrual pain. (4)
• Fever Management: Fever associated with infections, including viral illnesses in pediatric and adult populations. (5)
• Chronic Pain: Adjunctive use in osteoarthritis and rheumatoid arthritis. (6)

Ibuprofen & Paracetamol: Synergistic Central & Peripheral Mechanism of Action

Ibuprofen and paracetamol provide complementary pain relief by targeting distinct central and peripheral nervous system pathways. Paracetamol primarily acts centrally, inhibiting cyclooxygenase (COX) enzymes within the brain, particularly COX-3, to reduce pain perception and regulate temperature. It also enhances serotonergic descending pathways, contributing to its analgesic and antipyretic effects. Ibuprofen, on the other hand, acts peripherally as a nonsteroidal anti-inflammatory drug (NSAID), inhibiting COX-1 and COX-2 enzymes to reduce prostaglandin synthesis at the site of inflammation and addresses both inflammatory and nociceptive pain. The combination enables lower dosing of each component while maintaining or improving therapeutic outcomes, which in turn reduces the risk of side effects such as gastrointestinal discomfort and hepatotoxicity, enhancing patient safety and adherence. (7)

Effectiveness of Ibuprofen-Paracetamol: Clinical Evidence Stands Out Among Available Options

Better Pain Relief with Lower Dosage of Drug Use: In a randomized, double-blind trial with 735 patients experiencing postoperative dental pain, the fixed-dose combination (FDC) of ibuprofen 200 mg/paracetamol 500 mg provided significantly greater pain relief over 8 hours compared to ibuprofen 200 mg, ibuprofen 400 mg, paracetamol 500 mg, and paracetamol 1000 mg (p < 0.001). Fewer patients on FDC required rescue medication than those on placebo or monotherapy. (8)

Longer Fever-Free Periods than Paracetamol Monotherapy: In the PITCH trial, a randomized controlled study involving 156 children aged 6 months to 6 years with fever, the FDC of ibuprofen and paracetamol provided an additional 4.4 hours without fever over 24 hours compared to paracetamol alone and 2.5 hours compared to ibuprofen alone (p < 0.01). Approximately 82% of children treated with the FDC remained fever-free for 6 hours versus 64% with ibuprofen and 57% with paracetamol. (5)

Faster Onset and Greater Temperature Reduction than Monotherapy: In a randomized, double-blind trial involving 290 healthy males aged 18–55 with endotoxin-induced fever, the FDC of ibuprofen and paracetamol effectively reduced fever. Over 8 hours, the FDC lowered temperatures more than placebo by 3.14 weighted units (p=0.002), a measure that combines the magnitude and duration of temperature reduction. In the first 50–110 minutes, FDC reduced temperatures by 0.63 units more than the placebo (p< 0.001) and was 0.26 units better than ibuprofen alone (p=0.042). During the 80–110 minute window, the FDC was 0.38 units better than placebo (p < 0.001), 0.13 units better than ibuprofen alone (p = 0.045), and 0.13 units better than paracetamol alone(p = 0.049). (9)

Robust Evidence of Effective Pain Relief: In a meta-analysis of seven randomized controlled trials with 2,947 participants, the FDC of ibuprofen and paracetamol significantly improved pain relief compared to placebo. Patients receiving the FDC were 2.6 times more likely to achieve ≥50% pain relief (p < 0.00001) and required rescue medications 49% less often (p < 0.0001). (10)

Considering Guidelines Testimonies on Ibuprofen-Paracetamol Combination:

International and regional guidelines support the consideration of the ibuprofen-paracetamol combination when appropriately indicated:

• The American Dental Association (ADA) Science and Research Institute, endorsed by the ADA Council on Scientific Affairs in 2023, recommends the use of ibuprofen in combination with paracetamol for managing acute dental pain in children, as this combination likely reduces pain more effectively than either medication alone. (11)
• The expert consensus using the Nominal Group Technique (NGT), endorsed by a board of Italian pediatricians in 2023, recommends the fixed-dose combination of paracetamol and ibuprofen for managing acute mild-to-moderate pain in children. This combination was deemed superior in analgesic power compared to monotherapy, especially for headaches, earaches, odontalgia, and musculoskeletal pain. (12)
• The United States Food and Drug Administration (USFDA) recommends using the fixed-dose combination of ibuprofen and paracetamol to manage mild-to-moderate acute pain in adults. (13)
• The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) recommended the fixed-dose combination of ibuprofen and paracetamol for the short-term symptomatic treatment of mild to moderate pain in adults aged 18 years. (14) It is also approved by the Drug Controller General of India (DCGI). (15)
• The Indian Council of Medical Research (ICMR) Standard Treatment Workflows (STW) for the Management of Pharyngitis and Sore Throat recommended considering Ibuprofen or Paracetamol for managing pain in pharyngitis or folliculitis when indicated. (16)

Safety

The ibuprofen-paracetamol FDC exhibits an excellent safety profile, validated by clinical trials and meta-analyses. In a pooled analysis of seven clinical trials involving 1,477 participants, mild treatment-emergent adverse events (TEAEs,) such as nausea (13.5%) and dizziness (4.5%) occurred in less than 15% of cases, while severe adverse events (SAEs) were reported in only 2.2% of participants. Gastrointestinal disturbances, including dyspepsia, were minimal at 1.5%, significantly lower than with high-dose NSAID monotherapy​.(3)

Studies indicated that the combination of ibuprofen and paracetamol as safe and effective. Risks of hepatotoxicity and gastrointestinal bleeding were not elevated, and pharmacokinetics confirmed no drug interactions. The combination’s synergistic action enhanced analgesia at reduced doses, minimizing adverse events.(11)

Ibuprofen-paracetamol (400 mg/1000 mg) showed fewer adverse events (up to 30%), with consistently lower rates compared to NSAIDs like aceclofenac (34–36%) and diclofenac (up to 44%). Ibuprofen-paracetamol is recommended as a first-line anti-inflammatory agent due to its effective pain relief and lower risk of gastrointestinal and systemic complications, making them safer alternatives to aceclofenac and diclofenac, which are associated with higher risks of gastrointestinal and cardiovascular adverse effects, especially with long-term or high-dose use​. (18)

Take Home Message

• The ibuprofen-paracetamol combination remains an effective pain and fever management therapy due to its synergistic action supported by robust clinical efficacy.
• It provides faster and more sustained pain relief than monotherapy or other NSAID combinations.
• The combination’s dose-sparing effect reduces the risk of side effects, ensuring better patient safety and treatment compliance.
• With testimonies from various international and regional guidelines, it is a trusted choice for diverse pain and fever management conditions.
• The widely acceptable safety profile of the ibuprofen and paracetamol combination makes it a suitable and practical consideration across a broader patient population.

References:

1. Ostojic P, Radunovic G, Lazovic M, Tomanovic-Vujadinovic S. Ibuprofen plus paracetamol versus ibuprofen in acute low back pain: a randomized open label multicenter clinical study. Ibuprofen plus paracetamol versus ibuprofen in acute low back pain: a randomized open label multicenter clinical study. Acta Reumatol Port. 2017;42(1):18-25.

2. Bettiol A, Marconi E, Vannacci A, et al. Effectiveness of ibuprofen plus paracetamol combination on persistence of acute musculoskeletal disorders in primary care patients. Int J Clin Pharm. 2021;43(4):1045-1054.

3. Su J, Leyva R, Kellstein D, Cruz-Rivera M, Meeves S. Safety and tolerability of fixed-dose combinations of ibuprofen and acetaminophen: pooled analysis of phase 1-3 clinical trials. Postgrad Med. 2021;133(5):565-571.

4. Eccles R, Holbrook A, Jawad M. A double-blind, randomised, crossover study of two doses of a single-tablet combination of ibuprofen/paracetamol and placebo for primary dysmenorrhoea. Curr Med Res Opin. 2010;26(11):2689-2699.

5. Hay AD, Costelloe C, Redmond NM, et al. Paracetamol plus ibuprofen for the treatment of fever in children (PITCH): randomised controlled trial [published correction appears in BMJ. 2009;339:b3295]. BMJ. 2008;337:a1302. Published 2008 Sep 2.

6. Praveena KS, Pradhan S, Samson PL, Ofuoma O, Shwetha S, Dongre SK. Study of Fixed Dose Combinations of Paracetamol Available in India. J Young Pharm. 2022;14(4):444-6.

7. Kushner P, McCarberg BH, Wright WL, et al. Ibuprofen/acetaminophen fixed-dose combination as an alternative to opioids in management of common pain types. Postgrad Med. 2024;136(6):594-602.

8. Mehlisch DR, Aspley S, Daniels SE, Southerden KA, Christensen KS. A single-tablet fixed-dose combination of racemic ibuprofen/paracetamol in the management of moderate to severe postoperative dental pain in adult and adolescent patients: a multicenter, two-stage, randomized, double-blind, parallel-group, placebo-controlled, factorial study. Clin Ther. 2010;32(6):1033-1049.

9. Smith W, Leyva R, Kellstein D, Arthur E, Cruz-Rivera M. Efficacy of a Fixed-Dose Combination of Ibuprofen and Acetaminophen Compared With Individual Monocomponents in Adult Male Subjects With Endotoxin-Induced Fever: A Randomized Controlled Trial. Clin Ther. 2021;43(7):1213-1227.

10. Abushanab D, Al-Badriyeh D. Efficacy and Safety of Ibuprofen Plus Paracetamol in a Fixed-Dose Combination for Acute Postoperative Pain in Adults: Meta-Analysis and a Trial Sequential Analysis. CNS Drugs. 2021;35(1):105-120. doi:10.1007/s40263-020-00777-7

11. Carrasco-Labra A, Polk DE, Urquhart O, et al. Evidence-based clinical practice guideline for the pharmacologic management of acute dental pain in children: A report from the American Dental Association Science and Research Institute, the University of Pittsburgh School of Dental Medicine, and the Center for Integrative Global Oral Health at the University of Pennsylvania. J Am Dent Assoc. 2023;154(9):814-825.e2. doi:10.1016/j.adaj.2023.06.014

12. Parri N, Silvagni D, Chiarugi A, et al. Paracetamol and ibuprofen combination for the management of acute mild-to-moderate pain in children: expert consensus using the Nominal Group Technique (NGT). Ital J Pediatr. 2023;49(1):36. Published 2023 Mar 21. doi:10.1186/s13052-023-01445-4

13. COMBOGESIC® (acetaminophen and ibuprofen) tablets, for oral use. Initial U.S. approval: Accessed January 14, 2024. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/209471s000lbl.pdf.

14. European Medicines Agency (EMA), CHMP Assessment Report, "Paracetamol/Ibuprofen 500 mg / 150 mg Film-coated Tablets," EMA/517503/2017, 18 May 2017.Accessed on 16th January 2024

15. Drug Controller General of India (DCGI), Approval Notification for Paracetamol/Ibuprofen Fixed-Dose Combination, Public Records, India.Accessed on 16th January 2024 from https://cdsco.gov.in/opencms/resources/UploadCDSCOWeb/2018/UploadApprovalNewDrugs/dciApprovedfdc.pdf

16. Indian Council of Medical Research. Standard Treatment Workflows (STW) for the Management of Pharyngitis and Sore Throat. 2019 ed. Indian Council of Medical Research, Department of Health Research, Ministry of Health & Family Welfare; 2019. Diary No. 17206/2019-CO/L..Accessed on 16th January 2024.

17. Moore RA, Derry S, Aldington D, Wiffen PJ. Adverse events associated with single dose oral analgesics for acute postoperative pain in adults - an overview of Cochrane reviews. Cochrane Database Syst Rev. 2015;2015(10):CD011407. Published 2015 Oct 13.

18. ​​Indian Council of Medical Research, Department of Health Research, Ministry of Health and Family Welfare, Government of India. Standard Treatment Workflows of India, Vol. 3, 2022. New Delhi, India: Indian Council of Medical Research; 2022. Accessed on 16th January 2025

MAT-IN-2500113-1.0-01/2025

Disclaimer: This content is intended for Registered Medical Practitioners Only. Sanofi Consumer Healthcare India limited; Unit 1104, 11th Floor, Godrej Two, Pirojshanagar, Eastern Express Highway, Vikhroli East, Mumbai - 400079, Maharashtra, Indi